Restricted accessResearch articleFirst published online 2022-08
Perceptions of Risks and Benefits of Participating in HIV Cure-Related Research Among Diverse Young Adults Living with HIV in the United States: Qualitative Research Findings
In the United States, young adults have the highest rates of new HIV infections, and are less likely to be aware of their infection, be engaged in care, or achieve HIV viral suppression. As biomedical HIV research increasingly focuses on achieving long-term suppression without antiretroviral therapy (ART) and finding an HIV cure, little is known about perceptions of young adults living with HIV (YLWH) regarding HIV cure research. We recruited a diverse sample of 20 YLWH (18–29 years old) to participate in individual semistructured qualitative interviews to explore knowledge and perceptions of HIV cure research, and motivations and barriers to participation. Most participants had little knowledge of HIV cure research. Motivators of HIV cure research participation included altruism, stigma reduction, and the elimination of the clinical burdens of HIV. Barriers included potential physical side effects, psychological distress, the possibility of disclosure as a result of participating, and the amount of time required to participate. Most participants had concerns about analytic treatment interruptions (i.e., ART interruption to assess HIV remission), and indicated that they would want more frequent laboratory testing and protection for their sex partners during this time. Finally, participants suggested that, if other YLWH are considering participation in cure research, they should first learn as much as possible about the research, and then consider the potential personal benefits and the contribution that they could make to science and their communities. As HIV cure research advances, the participation of YLWH will be critical. Our study provides knowledge about how YLWH view HIV cure research. More sociobehavioral research is needed to ensure that those who are most likely to be the decision-makers and beneficiaries of an HIV cure are included at all levels of research.
Get full access to this article
View all access options for this article.
References
1.
Centers for Disease Control and Prevention: HIV SurveillanceReport, vol. 31, 2018. Available at www.cdc.gov/hiv/library/reports/hiv-surveillance.html, accessed October15, 2020.
2.
HorbergMA, HurleyLB, KleinDB, et al.: The HIV care cascade measured over time and by age, sex, and race in a large national integrated care system. AIDS Patient Care STDS, 2015; 29:582–590.
3.
ShawS, AmicoKR: Antiretroviral therapy adherence enhancing interventions for adolescents and young adults 13–24 years of age: A review of the evidence base. J Acquir Immune Defic Syndr (1999), 2016; 72:387.
4.
Control CfD: HIV andYouth, 2020. Available at https://www.cdc.gov/hiv/group/age/youth/index.html, accessed December15, 2020.
5.
ArnoldEM, SwendemanD, HarrisD, et al.: The stepped care intervention to suppress viral load in youth living with HIV: Protocol for a randomized controlled trial. JMIR Res Protoc, 2019; 8:e10791.
6.
KahanaSY, JenkinsRA, BruceD, et al.: Structural determinants of antiretroviral therapy use, HIV care attendance, and viral suppression among adolescents and young adults living with HIV. PLoS One, 2016; 11:e0151106.
7.
MastersMC, KruegerKM, WilliamsJL, MorrisonL, CohnSE: Beyond one pill, once daily: Current challenges of antiretroviral therapy management in the United States. Exp Rev Clin Pharmacol, 2019; 12:1129–1143.
8.
ZanoniBC, MayerKH: The adolescent and young adult HIV cascade of care in the United States: Exaggerated health disparities. AIDS Patient Care STDS, 2014; 28:128–135.
9.
JefferysR: Research Toward a CureTrials. Treatment Action Group, 2022. Available at www.treatmentactiongroup.org/cure/trials, accessed March2022.
10.
DubéK, EvansD, SyllaL, et al.: Willingness to participate and take risks in HIV cure research: Survey results from 400 people living with HIV in the US. J Virus Erad, 2017; 3:40.
11.
DubéK, TaylorJ, SyllaL, et al.: ‘Well, it's the risk of the unknown… right?’: A qualitative study of perceived risks and benefits of HIV cure research in the United States. PLoS One, 2017; 12:e0170112.
12.
SaberiP, EskafS, SaucedaJ, EvansD, DubéK: Perceptions of HIV virologic control strategies among younger and older age groups of people living with HIV in the United States: A cross-sectional survey. AIDS Res Hum Retroviruses, 2020; 36:606–615.
13.
SaberiP, CampbellCK, VenegasM, DubeK: Time to engage young people in HIV cure research. Aids Res Hum Retroviruses, 2022; 38:2–4.
14.
DubéK, EskafS, EvansD, et al.: The dose response: Perceptions of people living with HIV in the United States on alternatives to oral daily antiretroviral therapy. AIDS Res Hum Retroviruses, 2020; 36:324–348.
15.
RobertsC, CreamerE, BooneCA, YoungAT, MagnusM: Population representation in HIV cure research: A review of diversity within HIV cure studies based in the UnitedStates. AIDS Res Hum Retroviruses 2022 [Online ahead of print], DOI: 10.1089/AID.2021.0127.
16.
CoyneIT: Sampling in qualitative research. Purposeful and theoretical sampling; merging or clear boundaries? J Adv Nurs, 1997; 26:623–630.
17.
GuestG, BunceA, JohnsonL: How many interviews are enough? An experiment with data saturation and variability. Field Methods, 2006; 18:59–82.
18.
GuestG, NameyE, ChenM: A simple method to assess and report thematic saturation in qualitative research. PLoS One, 2020; 15:e0232076.
19.
GaleNK, HeathG, CameronE, RashidS, RedwoodS: Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol, 2013; 13:117.
20.
National Institutes of Health: NIH Priorities for HIV and HIV-Related Research. National Institutes of Health, Bethesda, MD, 2020.
21.
PerryKE, DubeK, Concha-GarciaS, et al.: “My death will not [be] in vain”: Testimonials from last gift rapid research autopsy study participants living with HIV at the end of life. AIDS Res Hum Retroviruses, 2020; 36:1071–1082.
22.
CohenMS, ChenYQ, McCauleyM, et al.: Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med, 2016; 375:830–839.
23.
RodgerAJ, CambianoV, BruunT, et al.: Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA, 2016; 316:171–181.
24.
DubéK, SimoniJ, LouellaM, et al.: Acceptability of cell and gene therapy for curing HIV infection among people living with HIV in the northwestern united states: A qualitative study. AIDS Res Hum Retroviruses, 2019; 35:649–659.
25.
SyllaL, EvansD, TaylorJ, et al.: If we build it, will they come? Perceptions of HIV cure-related research by people living with HIV in four US cities: A qualitative focus group study. AIDS Res Hum Retroviruses, 2018; 34:56–66.
26.
PoteatT, AqilA, CorbettD, EvansD, DubéK: “I would really want to know that they had my back”: Transgender Women's Perceptions of HIV Cure-Related Research in the United States. PLoS One, 2020; 15:e0244490.
27.
JulgB, DeeL, AnanworanichJ, et al.: Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—Report of a consensus meeting. Lancet HIV, 2019; 6:e259–e268.
28.
DubéK, HendersonGE, MargolisDM: Framing expectations in early HIV cure research. Trends Microbiol, 2014; 22:547–549.
29.
PelusoMJ, DeeL, CampbellD, et al.: A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. J Virus Erad, 2020; 6:34.
30.
BrownB, GaleaJT, DubéK, et al.: The need to track payment incentives to participate in HIV research. IRB Ethics Hum Res, 2018; 40:8–12.
31.
ChinLJ, BerensonJA, KlitzmanRL: Typologies of altruistic and financial motivations for research participation: A qualitative study of MSM in HIV vaccine trials. J Empir Res Hum Res Ethics, 2016; 11:299–310.
32.
ArnoldMP, EvansD, VergelN: Recruitment and ethical considerations in HIV cure trials requiring treatment interruption. J Virus Erad, 2015; 1:43.
33.
DubéK, DeeL: Willingness to risk death endpoint in HIV cure-related research with otherwise healthy volunteers is misleading. J Virus Erad, 2020; 6:81.
34.
FreshwaterW: From early AIDS vaccine to HIV cure research with analytical treatment interruption trials: A study participant testimonial. J Virus Erad, 2019; 5:231.
35.
HawleyC: ‘Fear overcome by love’: Why I participated in HIV cure research. J Virus Erad, 2018; 4:248.
36.
DubéK, HoseyL, StarrK, et al.: Participant perspectives in an HIV cure-related trial conducted exclusively in women in the United States: Results from AIDS clinical trials group 5366. AIDS Res Hum Retroviruses, 2020; 36:268–282.
37.
WuF, ZhangA, BabbittA, et al.: Overcoming HIV stigma? A qualitative analysis of HIV cure research and stigma among men who have sex with men living with HIV. Arch Sex Behav, 2018; 47:2061–2069.
38.
DubéK, AuerbachJD, StirrattMJ, GaistP: Applying the behavioural and social sciences research (BSSR) functional framework to HIV cure research. J Int AIDS Soc, 2019; 22:e25404.
39.
ProtiereC, ArnoldM, FiorentinoM, et al.: Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: A discrete choice experiment. J Int AIDS Soc, 2020; 23:e25443.
40.
DubéK, DeeL, EvansD, et al.: Perceptions of equipoise, risk–benefit ratios, and “otherwise healthy volunteers” in the context of early-phase HIV cure research in the United States: A qualitative inquiry. J Empir Res Hum Res Ethics, 2018; 13:3–17.
41.
PowerJ, DowsettGW, WestleA, et al.: The significance and expectations of HIV cure research among people living with HIV in Australia. PLoS One, 2020; 15:e0229733.
42.
PowerJ, WestleA, DowsettGW, et al.: Perceptions of HIV cure research among people living with HIV in Australia. PLoS One, 2018; 13:e0202647.
43.
EvansD: An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research. J Med Ethics, 2017; 43:100–103.
44.
SugarmanJ: HIV cure research: Expanding the ethical considerations. Ann Intern Med, 2013; 159:490–491.
45.
RandolphSD, GolinC, WelgusH, LightfootAF, HardingCJ, RigginsLF: How perceived structural racism and discrimination and medical mistrust in the health system influences participation in HIV health services for black women living in the United States South: A qualitative, descriptive study. J Assoc Nurses AIDS Care, 2020; 31:598–605.
46.
FosterC, AyersS, FidlerS: Antiretroviral adherence for adolescents growing up with HIV: Understanding real life, drug delivery and forgiveness. Ther Adv Infect Dis, 2020; 7:2049936120920177.
47.
DubéK, EvansD, DeeL, et al.: “We need to deploy them very thoughtfully and carefully”: Perceptions of analytical treatment interruptions in HIV cure research in the United States—A qualitative inquiry. AIDS Res Hum Retroviruses, 2018; 34:67–79.
48.
LauJS, SmithMZ, AllanB, et al.: perspectives on analytical treatment interruptions in people living with HiV and their health care providers in the landscape of HiV cure-focused studies. AIDS Res Hum Retroviruses, 2020; 36:260–267.
49.
PikeC, SigaqaL: Growing up with HIV. J Int AIDS Soc, 2020; 23:e25606.
50.
EyalN, DeeksSG: Risk to nonparticipants in HIV remission studies with treatment interruption: A symposium. J Infect Dis, 2019; 220(Supplement_1):S1–S4.
51.
LoVetteA, KuoC, HarrisonA: Strength-based interventions for HIV prevention and sexual risk reduction among girls and young women: A resilience-focused systematic review. Glob Public Health, 2019; 14:1454–1478.
52.
Michaels-IgbokweC, LagardeM, CairnsJ, Terris-PrestholtF, InitiativeI: Designing a package of sexual and reproductive health and HIV outreach services to meet the heterogeneous preferences of young people in Malawi: Results from a discrete choice experiment. Health Econ Rev, 2015; 5:9.
53.
MiallA, McLellanR, DongK, et al.: Bringing social context into global biomedical HIV cure-related research: An urgent call to action. J Virus Erad, 2022; 8:100062.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
